JP2005525991A5 - - Google Patents

Download PDF

Info

Publication number
JP2005525991A5
JP2005525991A5 JP2002588925A JP2002588925A JP2005525991A5 JP 2005525991 A5 JP2005525991 A5 JP 2005525991A5 JP 2002588925 A JP2002588925 A JP 2002588925A JP 2002588925 A JP2002588925 A JP 2002588925A JP 2005525991 A5 JP2005525991 A5 JP 2005525991A5
Authority
JP
Japan
Prior art keywords
bond
compound
pharmaceutically acceptable
virus infection
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002588925A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525991A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/015383 external-priority patent/WO2002092006A2/en
Publication of JP2005525991A publication Critical patent/JP2005525991A/ja
Publication of JP2005525991A5 publication Critical patent/JP2005525991A5/ja
Withdrawn legal-status Critical Current

Links

JP2002588925A 2001-05-16 2002-05-15 核酸ベースの化合物およびその使用方法 Withdrawn JP2005525991A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29147101P 2001-05-16 2001-05-16
PCT/US2002/015383 WO2002092006A2 (en) 2001-05-16 2002-05-15 Nucleic acid-based compounds and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009178281A Division JP2009242439A (ja) 2001-05-16 2009-07-30 核酸ベースの化合物およびその使用方法
JP2013124544A Division JP2013177453A (ja) 2001-05-16 2013-06-13 核酸ベースの化合物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2005525991A JP2005525991A (ja) 2005-09-02
JP2005525991A5 true JP2005525991A5 (enExample) 2006-01-05

Family

ID=23120429

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2002588925A Withdrawn JP2005525991A (ja) 2001-05-16 2002-05-15 核酸ベースの化合物およびその使用方法
JP2009178281A Pending JP2009242439A (ja) 2001-05-16 2009-07-30 核酸ベースの化合物およびその使用方法
JP2013124544A Pending JP2013177453A (ja) 2001-05-16 2013-06-13 核酸ベースの化合物およびその使用方法
JP2015024999A Withdrawn JP2015091891A (ja) 2001-05-16 2015-02-12 核酸ベースの化合物およびその使用方法
JP2017062815A Pending JP2017119712A (ja) 2001-05-16 2017-03-28 核酸ベースの化合物およびその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2009178281A Pending JP2009242439A (ja) 2001-05-16 2009-07-30 核酸ベースの化合物およびその使用方法
JP2013124544A Pending JP2013177453A (ja) 2001-05-16 2013-06-13 核酸ベースの化合物およびその使用方法
JP2015024999A Withdrawn JP2015091891A (ja) 2001-05-16 2015-02-12 核酸ベースの化合物およびその使用方法
JP2017062815A Pending JP2017119712A (ja) 2001-05-16 2017-03-28 核酸ベースの化合物およびその使用方法

Country Status (7)

Country Link
US (3) US6881831B2 (enExample)
JP (5) JP2005525991A (enExample)
KR (2) KR100991975B1 (enExample)
CN (2) CN101113160A (enExample)
AU (1) AU2002316118A1 (enExample)
GB (1) GB2392157B (enExample)
WO (1) WO2002092006A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092006A2 (en) * 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
US7635686B2 (en) * 2001-10-03 2009-12-22 Bioniche Life Sciences, Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
WO2005078094A2 (en) * 2004-02-06 2005-08-25 Dharmacon, Inc. Stabilized rnas as transfection controls and silencing reagents
US20090280567A1 (en) * 2004-02-06 2009-11-12 Dharmacon, Inc. Stabilized sirnas as transfection controls and silencing reagents
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US7923206B2 (en) * 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7935811B2 (en) * 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US20060223777A1 (en) * 2005-03-29 2006-10-05 Dharmacon, Inc. Highly functional short hairpin RNA
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2008036841A2 (en) * 2006-09-22 2008-03-27 Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
CN102123716B (zh) * 2008-04-03 2013-09-18 春堤公司 用于治疗病毒感染的化合物和方法
CN107973833A (zh) * 2010-08-30 2018-05-01 斯普林银行医药公司 作为治疗剂的寡核苷酸类似物的设计
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
EP3365375A4 (en) 2015-10-20 2019-09-04 Sorrento Therapeutics, Inc. COMPOUNDS FOR INTRA-CELLULAR ADMINISTRATION
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
CN111918870B (zh) * 2018-05-18 2022-07-08 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
CN113164506B (zh) * 2018-12-06 2023-12-08 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
CN115768778A (zh) 2020-04-21 2023-03-07 配体药物公司 苄氧基磷酸(膦酸)酯化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218103A (en) * 1988-05-26 1993-06-08 University Patents, Inc. Nucleoside thiophosphoramidites
FR2641537A1 (fr) 1989-01-09 1990-07-13 Centre Nat Rech Scient Phosphates d'oxysteryle, synthese et utilisation comme agent pharmaceutique
US5149798A (en) 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
ZA902912B (en) * 1989-04-21 1991-01-30 Cornell Res Foundation Inc Method of inhibiting induction of latent or chronic viral infection
US5149796A (en) * 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US5212293A (en) * 1990-08-06 1993-05-18 American Cyanamid Company Process for the preparation of deoxynucleosides
DE4111730A1 (de) 1991-04-10 1992-10-15 Knoll Ag Neue cytarabin-derivate, ihre herstellung und verwendung
GB2257704B (en) * 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
ATE221127T1 (de) * 1991-10-15 2002-08-15 Isis Pharmaceuticals Inc Über chirale phosphoratome gebundene oligonukleotide
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
WO1994000472A2 (en) 1992-06-30 1994-01-06 Research Corporation Technologies, Inc. Trivalent synthesis of oligonucleotides containing stereospecific alkylphosphonates and arylphosphonates
WO1994000473A2 (en) 1992-06-30 1994-01-06 Res Corp Technologies Inc Pentavalent synthesis of oligonucleotides containing stereospecific alkylphosphonates and arylphosphonates
AU6449394A (en) 1993-03-30 1994-10-24 Sterling Winthrop Inc. Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5843912A (en) * 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
AU3725895A (en) * 1994-10-06 1996-05-02 New York University Administration of a 27-hydroxycholesterol or prodrug thereof as an anti-cancer agent
KR100484124B1 (ko) 1994-10-17 2005-09-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 변형된 뉴클레오티드 결합부위를 갖는 dna 서열화용 dna 폴리머라제
AU5871196A (en) 1995-05-23 1996-12-24 Hybridon, Inc. Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
EP0831854A4 (en) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5705621A (en) 1995-11-17 1998-01-06 Isis Pharmaceuticals, Inc. Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
EP2256133B1 (en) 1997-01-08 2016-12-14 Sigma-Aldrich Co. LLC Bioconjugation of macromolecules
EP1086064A2 (en) 1998-06-10 2001-03-28 Glycodesign Inc. Directed combinatorial compound library and high throughput assays for screening same
AU1916201A (en) * 1999-11-08 2001-06-06 Origenix Technologies, Inc. Combinatorial library synthesis and pharmaceutically active compounds produced thereby
AU1656601A (en) 1999-11-12 2001-06-12 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
WO2002043771A2 (en) 2000-12-01 2002-06-06 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
WO2002092006A2 (en) 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2005525991A5 (enExample)
ES2566632T3 (es) Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm
JP2005526857A5 (enExample)
US6476000B1 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
RU2002101317A (ru) Новые бициклонуклеозидные аналоги
CA2632626A1 (en) Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
JP4959900B2 (ja) 抗ウイルスピリミジンヌクレオシド類
JP2020022483A5 (enExample)
KR920002625A (ko) 말단에 3'-3' 또는 5'-5' 뉴클레오타이드간 결합을 갖는 올리고뉴클레오타이드 유사체
LU91036I2 (fr) Adefovir dipivoxil et ses dérivés pharmaceutiquement acceptables (hepsera)
CN100400045C (zh) 基于核酸的化合物及其使用方法
JP2004537516A5 (enExample)
CA2537114A1 (en) Tricyclic nucleosides or nucleotides as therapeutic agents
JP2007504830A5 (enExample)
JP2005523922A5 (enExample)
JP2014054250A5 (enExample)
JP2002541233A5 (enExample)
RU2020115761A (ru) МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В
JP2019533472A5 (enExample)
JP2004503564A5 (enExample)
JP2007520452A5 (enExample)
JP2021090458A5 (enExample)
KR970701198A (ko) 3'-치환 뉴클레오시드 유도체(3'-substituted nucleoside derivative)
RU96118248A (ru) 3'-замещенное производное нуклеозида
JP2021506246A5 (enExample)